Back to top

Craig-Hallum Remains a Buy on Champions Oncology (CSBR)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Champions Oncology, with a price target of $12.00. The company...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Champions Oncology, Inc. (CSBR)